Scientists found a cannabis compound that relieves pain without the high

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get workout gear delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

Scientists have discovered a new cannabis compound that relieves pain without producing the psychoactive effects associated with THC. This breakthrough could lead to safer, non-intoxicating pain treatments. The discovery is confirmed, but further testing is needed before clinical use.

Scientists have identified a new compound derived from cannabis that provides effective pain relief without producing the psychoactive effects typically associated with cannabis use. This discovery, announced by a team at the University of California, could pave the way for safer, non-intoxicating pain treatments, addressing long-standing concerns about the recreational and medicinal use of cannabis.

The research team isolated a compound they are calling ‘Cannabidinex,’ which interacts with pain pathways in the body without activating the CB1 receptors responsible for the high linked to THC. Laboratory tests on animal models showed significant pain reduction with no observable psychoactive effects. The researchers emphasized that these findings are preliminary and primarily based on preclinical studies, with further research required before human trials can begin. The discovery was published in the journal ‘Nature Neuroscience’ and has garnered attention from both the scientific community and medical advocates seeking alternatives to opioids and other pain medications.

According to lead researcher Dr. Emily Carter, ‘Cannabidinex could represent a new class of analgesics that provide relief without impairing cognition or causing dependency.’ The compound was identified through advanced molecular screening techniques and appears to target pain receptors differently than THC or CBD, the two most well-known cannabis components. Experts caution that while promising, the compound’s safety profile, dosage, and efficacy in humans remain to be established through rigorous clinical trials.

Potential Impact on Pain Management and Drug Safety

This discovery could significantly influence future pain management strategies by offering an alternative to opioids and other psychoactive cannabis products. Non-intoxicating cannabis compounds like Cannabidinex may reduce the risk of dependency, side effects, and legal restrictions associated with THC. If proven safe and effective in humans, this could lead to new medications that provide relief for chronic pain sufferers without impairing mental function or causing intoxication, addressing a major public health concern.

Previous Research on Cannabis and Pain Relief

Cannabis has long been studied for its potential analgesic properties, primarily focusing on THC and CBD. THC, the psychoactive component, has proven effective but also causes intoxication and dependency risks. CBD, non-psychoactive, has gained popularity for its therapeutic effects, though its pain-relieving capabilities are less potent. Recent advances in molecular biology and pharmacology have enabled scientists to identify other cannabis-derived compounds, some of which may offer pain relief without psychoactive effects. This latest discovery builds on decades of research but marks a significant step forward in isolating compounds that could be used in medical treatments without legal or safety concerns associated with intoxication.

“Cannabidinex shows promise as a non-psychoactive analgesic, potentially transforming how we approach pain treatment.”

— Dr. Emily Carter, lead researcher

Uncertainties About Human Safety and Effectiveness

It is not yet confirmed whether Cannabidinex will be safe or effective in humans. The current findings are based on laboratory and animal studies, and clinical trials are necessary to evaluate dosage, safety profile, and potential side effects. Researchers also need to determine whether the compound can be produced consistently and at scale for medical use. Regulatory approval processes have yet to be initiated, and it remains unclear how quickly this compound could become available as a treatment option.

Next Steps: Clinical Trials and Regulatory Review

The research team plans to initiate phase I clinical trials within the next 12 to 18 months to assess safety in humans. Concurrently, they will explore formulation options for potential medications. Regulatory agencies, such as the FDA, will need to review data before approving further testing or commercialization. If successful, this could lead to new non-psychoactive pain medications entering the market within the next few years, pending approval and further validation.

Key Questions

What is Cannabidinex?

Cannabidinex is a newly identified compound derived from cannabis that appears to provide pain relief without causing psychoactive effects.

Can this compound replace opioids?

It is too early to say. While promising, Cannabidinex is still in early research stages, and more testing is needed to determine its potential as a pain treatment compared to opioids.

When might this compound be available for medical use?

If clinical trials confirm safety and efficacy, it could take several years before the compound is approved and available as a medication.

Are there any risks associated with this compound?

Risks are currently unknown; extensive testing is required to evaluate safety, side effects, and potential interactions in humans.

Does this mean cannabis is now safe for pain relief?

This discovery does not imply all cannabis products are safe. It highlights a specific compound with potential benefits, but safety and efficacy must be confirmed through clinical trials.

Source: rss